Host biology drives malaria treatment failures, reveals RGCB study
Researchers at the Rajiv Gandhi Centre for Biotechnology discovered that malaria treatment failures are often caused by host biology rather than parasite mutations. Specifically, young red blood cells called reticulocytes provide a protective environment that shields the malaria parasite from artemisinin-based treatments.
Why it matters
This discovery challenges the current understanding of drug resistance and could lead to more effective malaria treatment strategies.
For decades now, combination therapies with Artemisinin, a potent anti-malarial drug, have been the cornerstone of malaria treatment worldwide. It has always vexed scientists that some malaria patients failed to clear the parasite and went into relapse despite receiving the right treatment.
The report is a straightforward summary of scientific research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in